Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Undergoing Ultra-Low Anterior Resection

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorTongji Hospital

About this trial

The goal of this clinical trial is to learn if somatostatin plus a clear liquid diet can help prevent severe leakage after rectal cancer surgery in adults with low or mid rectal cancer who are scheduled to have ultra-low anterior resection. These patients have a higher risk of leakage where the bowel is joined together after surgery.

The main questions it aims to answer are:

Does somatostatin plus a clear liquid diet prevent severe leakage within 1 month after surgery about as well as a prophylactic diverting stoma?

What medical problems, bowel function problems, recovery outcomes, and quality of life outcomes do participants have after surgery and during follow-up?

Researchers will compare somatostatin plus a clear liquid diet without a diverting stoma to prophylactic diverting stoma to see if the somatostatin plus clear liquid diet regimen can provide similar protection against severe leakage while reducing the need for stoma creation.

Participants will:

Have rectal cancer surgery with the bowel joined very close to the anus

Be randomly assigned to receive either somatostatin plus a clear liquid diet for 7 days after surgery without a diverting stoma, or a prophylactic diverting stoma

Have follow-up assessments of leakage, postoperative complications, bowel function, recovery quality, and quality of life

Complete follow-up visits or assessments for up to 3 years after surgery

Eligibility criteria

Qualifiers

Adults aged 18 to 75 years

Patients with stage I to III rectal malignancy who are scheduled to undergo low anterior resection at a participating gastrointestinal surgery center

The lower edge of the tumor is 8 cm or less from the dentate line, or 10 cm or less from the anal verge, based on preoperative colonoscopy, imaging, or digital rectal examination

The planned anastomosis is expected to be 2 cm or less from the dentate line, or 4 cm or less from the anal verge

Disqualifiers

Has another colorectal malignant tumor at the same time

The final anastomosis after surgery is more than 2 cm from the dentate line, or more than 4 cm from the anal verge

Has metastatic disease before surgery

Is pregnant

Trial design

Treatments tested in this trial

  • Somatostatin
  • Clear Liquid Diet
  • Prophylactic Diverting Stoma

Treatment groups

72 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Tongji Hospital

Lead sponsor

Ezhou Central Hospital

Collaborator

Shanxi Bethune Hospital

Collaborator

Taihe Hospital affiliated to Hubei University of Medicine

Collaborator

Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University

Collaborator